Compare VVR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVR | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.6M | 472.9M |
| IPO Year | 1998 | 2015 |
| Metric | VVR | ZVRA |
|---|---|---|
| Price | $3.12 | $10.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 805.1K | 694.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $7.26 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $3.03 | $6.85 |
| 52 Week High | $3.83 | $13.16 |
| Indicator | VVR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 63.24 |
| Support Level | $3.03 | $8.29 |
| Resistance Level | $3.31 | $11.19 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 48.89 | 98.12 |
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.